Efficacy and safety of two triple regimen on patients with newly diagnosed type 2 diabetes: randomized, control trial

Two triple therapy on patients with newly dianosed type 2 diabetes: randomized, control study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400089972

Enrollment

Unknown

Registered

2024-09-20

Start date

2024-10-08

Completion date

Unknown

Last updated

2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

semaglutide group:metformin+empagliflozin+semaglutide

iGlarLixi group:metformin+empagliflozin+iGlarLixi

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. newly diagnosed type 2 diabetes; 2. =9.0%.

Exclusion criteria

Exclusion criteria: 1. type 1 diabetes; 2. eGFR<45; 3. having coronary heart disease, tumors, and pregnancy; 4. taking glucocorticoid.

Design outcomes

Primary

Measure	Time frame
HbA1c;	—

Secondary

Measure	Time frame
time in range;rate of remission;	—

Countries

China

Contacts

Public ContactWangen Li

the Second Affiliated Hospital of Guangzhou Medical University

liwg660@126.com+86 135 0003 1715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026